Abstract
Abciximab, heparin, and clopidogrel are often used together in the setting of coronary syndromes. These drugs are associated with thrombocytopenia and it is important to quickly discriminate the cause of this complication as it has implications for the management of thrombocytopenia and the coronary syndrome. This case highlights some of the dilemmas that may arise as no test can definitively identify the offending drug, and stopping these drugs can affect the outcome of the coronary event including stent thrombosis. Keywords: profound thrombocytopenia; abciximab; heparin; clopidogrel
Full Text
The Full Text of this article is available as a PDF (61.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berkowitz S. D., Harrington R. A., Rund M. M., Tcheng J. E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation. 1997 Feb 18;95(4):809–813. doi: 10.1161/01.cir.95.4.809. [DOI] [PubMed] [Google Scholar]
- Coukell A. J., Markham A. Clopidogrel. Drugs. 1997 Nov;54(5):745–751. doi: 10.2165/00003495-199754050-00006. [DOI] [PubMed] [Google Scholar]
- Dasgupta H., Blankenship J. C., Wood G. C., Frey C. M., Demko S. L., Menapace F. J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000 Aug;140(2):206–211. doi: 10.1067/mhj.2000.107554. [DOI] [PubMed] [Google Scholar]
- Ferguson J. J., Kereiakes D. J., Adgey A. A., Fox K. A., Hillegass W. B., Jr, Pfisterer M., Vassanelli C. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J. 1998 Apr;135(4):S77–S89. doi: 10.1016/s0002-8703(98)70300-x. [DOI] [PubMed] [Google Scholar]
- Holmes M. B., Kabbani S., Watkins M. W., Battle R. W., Schneider D. J. Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia. Circulation. 2000 Feb 29;101(8):938–939. doi: 10.1161/01.cir.101.8.938. [DOI] [PubMed] [Google Scholar]
- Kereiakes D. J., Berkowitz S. D., Lincoff A. M., Tcheng J. E., Wolski K., Achenbach R., Melsheimer R., Anderson K., Califf R. M., Topol E. J. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J. 2000 Jul;140(1):74–80. doi: 10.1067/mhj.2000.106615. [DOI] [PubMed] [Google Scholar]
- Lincoff A. M., Mark D. B., Tcheng J. E., Califf R. M., Bala M. V., Anderson K. M., Davidson-Ray L., Knight J. D., Cabot C. F., Topol E. J. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 2000 Dec 12;102(24):2923–2929. doi: 10.1161/01.cir.102.24.2923. [DOI] [PubMed] [Google Scholar]
- Oomen P. H., Tulleken J. E., Zijlstra J. G. Hemolytic uremic syndrome in a patient treated with clopidogrel. Ann Intern Med. 2000 Jun 20;132(12):1006–1006. doi: 10.7326/0003-4819-132-12-200006200-00025. [DOI] [PubMed] [Google Scholar]